系统性红斑狼疮患者血清IL-18、sVCAM-1和VEGF水平及其意义

目的探讨白细胞介素18（IL-18）、可溶性血管黏附分子-1（sVCAM-1）和血管内皮生长因子（VEGF）水平变化与系统性红斑狼疮（SLE）发病机制的关系。方法采用酶联免疫ELISA法检测SLE患者35例，正常对照组25例血清IL-18、sVCAM-1和VEGF的水平。结果SLE组IL-18（521．23±134．29）pg／mL、sVCAM-1（1179．25±225．57）ng／mL、VEGF（198．85±41．96）pg／mL，较正常对照组IL-18（256．39±59．52）pg／mL、sVCAM．1（538．16±91．21）ng／mL、VEGF（125．62±32．15）pg／mL明显升高，差异有统计学意义（P均〈0．01）。活动期SLE患者IL-18（687．44±158．60）pg／mL、sVCAM．1（1478．14±322．72）ng／mL、VEGF（236．25±48．62）pg／mL与非活动期组sLEIL—18（355．02±109．98）pg／mL、sVCAM-1（881．37±128．30）ng／mL、VEGF（160．47±35．79）pg／ml之间比较，差异有统计学意义（P均〈0．01）。结论SLE患者IL-18、sVCAM-1和VEGF水平增高，且与疾病的活动性相关。

Determination and Clinical Significance of Serum Levels of IL-18, sVCAM-1 and VEGF in Patients with SLE

Objective To study the serum levels of interleukin 18 （IL- 18 ）, soluble vascular adhesion molecule （sVCAM-1） and Vascular endothelial growth factor （VEGF）in patients with systemic lupus erythematosus （SLE） and their clinical significance. Methods Enzyme linked immunosorbent assay（ELISA） was used to detect IL- 18, sVCAM-I and VEGF in serums of 35 patients with SLE and 25 normal controls. Results The serum levels of IL-18, sVCAM-1 and VEGF in patients with SLE [ （521.23 ±134.29）pg/mL, （ 1179.75±225.57）ng/mL, （198.85 ± 41.96）pg/mL] were significantly higher than those in controls[（256.39±59.52）pg/mL, （538.16±91.21）ng/mL, （125.62±32.15）pg/mL] （P〈0.01）. And the levels of IL-18, sVCAM-1 and VEGF [ （687.44±158.60）pg/mL, （1478.14±322.72）ng/mL, （236.25±48.62）pg/mL] in active systemic lupus erythematosus patients were higher than those in non-active systemic lupus erythematosus patients [（355.02 ±109.98）pg/mL, （881.37 ±128.30）ng/mL, （160.47±35.79）pg/mL] （P〈0.01）. Conclusion The serum levels of IL-18, sVCAM-1 and VEGF in SLE were higher in the SLE patients than those in control group, and were related to the activities of SLE.